

AbbVie Inc. (ABBV) - ANALYST REPORT

Executive Summary with Comprehensive Analysis

Date: 2026-03-27 | Current Price: \$209.40 | Strategy: No Active Position

■ QUICK DECISION

Action: WAIT | Confidence: LOW | Signal Strength: 0/7

EXECUTIVE SUMMARY - Essential Metrics

TECHNICAL METRICS	VALUE	FUNDAMENTAL METRICS	VALUE
Current Price	\$209.40	Market Cap	\$370.4B
Past Win Rate (Backtest)	70.0%	Forward P/E	13.0x
Past Total Return	+59.1%	Analyst Target	\$249.14
RSI / Trend Strength	38 / 25	Upside to Target	+19.0%
MACD Signal	Bearish	Revenue Growth	+10.0%
Profit Factor	3.31	Institutional Own.	76.4%
Open Position	No open position	Analyst Ratings	20 Buy / 8 Hold / 1 Sell

■ TECHNICAL ANALYSIS SUMMARY

Indicator	Value	Signal
EMA 20	\$215.82	Bearish
EMA 50	\$220.37	Bearish
RSI (14)	37.6	Weak - potential support
Trend Strength (ADX)	25.2	Strong trend (25-50)

■ CONSENSUS & INVESTMENT RATIONALE

RATING	BUY
Target Price	\$249.14
Upside/Downside	+19.0%
Risk/Reward	1.27:1
Time Horizon	6-12 months

Investment Rationale: Our BUY rating is based on: (1) Technical backtest showing 70.0% win rate with +59.1% total return over backtest period, (2) +19.0% upside to analyst consensus target of \$249.14, (3) Moderate fundamental growth profile with +10.0% revenue growth, and (4) 76.4% institutional ownership indicating high conviction from professional investors.

Action: No confluence signal (score=0). Wait for score ≥ 5 before deploying capital.

Technical Signal: Confluence 0/7 (threshold: 5) | **Risk/Reward:** Neutral

■ KEY INSIGHT

The chandelier strategy has proven effective (Win Rate: 70.0%, Avg Return: +12.7%), but patience is critical. Only enter on confirmed signals with proper risk management. Current technical confluence of 0 does not meet entry threshold of 5 - remain on

sidelines. Fundamental backdrop shows 0% earnings growth with 76% institutional ownership, indicating strong conviction from professional investors.

■ INTELLIGENT STOP LOSS STRATEGY

METRIC	VALUE	DETAILS
Current Price	\$209.40	Latest market price
Buy Stop Loss	\$198.01	Conservative 2.0x ATR (5.4% distance)
Position Stop Loss	\$198.01	Hybrid 2.00x ATR (5.4% distance)
ATR (14-day)	\$5.70	Volatility: 2.7% of price
ADX Strength	25.2	Strong trend

Status: New position - Standard stop loss levels

ADX: 20-25 = Emerging trend | 25-50 = Strong trend | 50+ = Very strong

■ Strategy Comparison: Conservative vs Hybrid

METRIC	CONSERVATIVE (2.0x ATR)	HYBRID (Adaptive)
Past Win Rate	70%	76%
Past Total Return	+59.1%	+77.6%
Max Drawdown	-13.2%	-11.1%
Total Trades	10	17
Position	NONE	NONE

Both strategies analyzed independently. Conservative uses fixed 2.0x ATR stops. Hybrid adapts stops based on position profit.

For the latest stock analysis, support, resistance and interactive charts, visit [Ultra Stock Analysis Pro](#)

■ ANALYST RATING CHANGES - COMPLETE HISTORY

All recent upgrades, downgrades, and price target changes (last 90 days)

Firm	Action	From → To	Date
RBC Capital	INITIATED	Outperform	Feb 25, 2026
Barclays	INITIATED	Overweight	Feb 20, 2026
Wolfe Research	DOWNGRADE	Outperform → Peer Perform	Jan 08, 2026

Analyst Price Targets

Average Target: \$249.14 (+19.0% from current)

High Target: \$299.00 (+42.8%)

Low Target: \$184.00 (-12.1%)

Current Price: \$209.40

DETAILED ANALYSIS: BUY-SIDE PERSPECTIVE

In-Depth Portfolio Management Analysis

Expected Returns & Position Sizing

Based on backtest performance (Win Rate: 70.0%, Avg Return: +12.7%) and analyst consensus (Target: \$249.14, +19.0% upside), an **OVERWEIGHT** exposure may be considered. Risk/Reward ratio of 1.27:1 suggests moderate risk-adjusted returns. No current position - opportunity to establish entry at favorable technical levels.

Catalyst Calendar & Timing

Next Major Catalyst: May 01, 2026 earnings report

Seasonality: Historical analysis shows positive momentum in backtest period

Technical Setup: Neutral - waiting for confluence signal

Institutional Activity: 76.4% institutional ownership (Largest: Vanguard Group Inc)

Short Interest: 1.4% of float - Moderate short interest

Liquidity Profile

Average Volume: 7.2M shares/day - Lower liquidity

Market Cap: \$370.4B - Large cap

Beta: 0.33 - Lower than market volatility

Execution Risk: Moderate for institutional-sized positions

SELL-SIDE PERSPECTIVE - Investment Research Analysis

Investment Thesis

AbbVie Inc. operates in the Healthcare sector (Drug Manufacturers - General). Current valuation of 13.0x forward P/E reflects discounted multiples relative to growth prospects. Operating margin of 34.1% shows strong profitability. **Fundamental Outlook:** Moderate Growth - Monitoring profitability amid revenue expansion

Valuation Analysis

Forward P/E: 13.0x

Trailing P/E: 88.4x

Price/Sales: 6.06x - Premium valuation

Price/Book: -113.19x

Enterprise Value: \$433.4B

EV/Revenue: 7.09x (vs industry avg)

Competitive Positioning & Market Share

Key Competitors: Various industry players

U.S. Market Share: 0% - Competitive player

Global Market Share: 0%

Competitive Advantages: Market position, Technology, Brand

Key Products: Core products and services

Institutional Sentiment & Ownership

Institutional Ownership: 76.4% - Very high institutional confidence

Largest Holder: Vanguard Group Inc (180.8M shares)

Analyst Coverage: 29 analysts

Consensus: 20 Buy, 8 Hold, 1 Sell - Bullish sentiment

■ 7-DAY NEWS SENTIMENT ANALYSIS

Market Sentiment from Recent Financial News

METRIC	VALUE	ANALYSIS
Overall Score	+3.6 / 10	Slightly Bullish
Articles Analyzed	10	Last 7 days (top 5 shown per category)
Bullish Articles	6 (60%)	Positive sentiment
Bearish Articles	0 (0%)	Negative sentiment
Neutral Articles	4 (40%)	Mixed/Neutral tone

■ TOP BULLISH HEADLINES

1. Can New Drugs Drive J&J's Innovative Medicine Despite Stelara LOE? (Zacks, Mar 27)

JNJ's Innovative Medicine unit eyes Q1 growth on key drug momentum, but biosimilar pressure and Stelara's decline may weigh on results....

Source: <https://finance.yahoo.com/sectors/healthcare/articles/drugs-drive-j-js-innovativ>

2. 3 Stocks That May Be Underestimated In March 2026 (Simply Wall St., Mar 27)

Over the last 7 days, the United States market has experienced a 1.6% decline, yet it has shown resilience with a 15% rise over the past year and an a...

Source: <https://finance.yahoo.com/markets/stocks/articles/3-stocks-may-underestimated-ma>

3. VHT Lagged the Market by 57 Points Over 5 Years. Here Is Why Long-Term Investors Still Hold It (24/7 Wall St., Mar 26)

Healthcare spending doesn't stop during recessions. That structural reality is the core argument for owning Vanguard Health Care ETF (NYSEARCA:VHT), a...

Source: <https://247wallst.com/investing/2026/03/26/vht-lagged-the-market-by-57-points-ov>

4. ABBV- An Attractive Income Stock in this Turbulent Market (MoneyShow, Mar 27)

It has been a tough market. The uncertainty surrounding the war with Iran is taking a toll. But one stock in particular should be worth enduring possi...

Source: <https://finance.yahoo.com/markets/stocks/articles/abbv-attractive-income-stock-t>

5. J&J's Pipeline Surge Sets Up Stronger Growth From New Drugs in 2026 (Zacks, Mar 26)

JNJ's rapid pipeline progress and new drug approvals in 2025 set the stage for stronger growth impact from its expanding portfolio in 2026....

Source: <https://finance.yahoo.com/sectors/healthcare/articles/j-js-pipeline-surge-sets-1>

■ SENTIMENT INTERPRETATION

The news sentiment is **moderately bullish**, showing generally positive coverage with some caution. Market perception appears favorable but not overwhelmingly positive. This neutral-to-positive sentiment suggests steady conditions without extreme optimism.

DEEP DIVE: COMPREHENSIVE RISK ASSESSMENT

Detailed Risk Factors and Mitigation Strategies

Key Risks & Mitigants

Company-Specific Risks:

- Competition
- Market conditions
- Regulatory changes

Technical Risk Factors:

- Win Rate: 70.0% (7 wins, 3 losses)
- Profit Factor: 3.31x (Avg Win 20.8% vs Avg Loss -6.3%)
- Current Confluence: 0 (Last: 3 on Mar 20) - No setup - awaiting signal
- Volatility (ATR 14): \$5.70 (2.7% of price) - Stop loss typically 2-3x ATR

Market Risk:

- Beta: 0.33 - Below-average market sensitivity
- Short Interest: 1.4% - Normal short activity

REFERENCE: APPENDIX A - Complete Technical Indicators

Comprehensive Technical Data for Quantitative Analysis

Indicator	Value	Interpretation
EMA 20	\$215.82	Short-term trend
EMA 50	\$220.37	Medium-term trend
EMA 200	\$213.54	Long-term trend
Relative Strength	37.6	Weak - potential support
MACD	-5.17	Bearish
MACD Signal	-3.93	Signal line
MACD Histogram	-1.24	Bearish
Volatility (ATR 14)	\$5.70	2.7% of price
Trend Strength (ADX)	25.2	Strong trend (25-50)
+DI	17.9	Positive directional movement
-DI	28.7	Negative directional movement
Stochastic %K	25.2	Neutral
Stochastic %D	18.8	Oversold
Bollinger Upper	\$242.36	Resistance zone
Bollinger Middle	\$219.63	Moving average
Bollinger Lower	\$196.90	Support zone
VWAP	\$210.67	Volume-weighted average

REFERENCE: APPENDIX B - Complete Fundamental Metrics

Comprehensive Fundamental Data for Financial Analysis

Category	Metric	Value	Interpretation
Valuation	Market Cap	\$370.4B	Total market value
Valuation	Enterprise Value	\$433.4B	Total company value
Valuation	Forward P/E	13.0x	Price to forward earnings
Valuation	Trailing P/E	88.4x	Price to trailing earnings
Valuation	PEG Ratio	0.50	P/E relative to growth
Valuation	Price/Sales	6.06x	Market cap to revenue
Valuation	Price/Book	-113.19x	Price to book value
Valuation	EV/Revenue	7.09x	Enterprise value to revenue
Valuation	EV/EBITDA	14.8x	Enterprise value to EBITDA
Performance	Revenue (TTM)	\$61.2B	Trailing 12-month revenue
Performance	Revenue Growth	+10.0%	Year-over-year growth
Performance	Earnings Growth	+0.0%	Earnings growth rate
Performance	EPS Growth (Next Yr)	+580.0%	Forward EPS growth estimate
Performance	Gross Profit	\$43.8B	Revenue minus COGS
Performance	Operating Income	\$19.0B	EBIT
Performance	Net Income	\$4.2B	Bottom line profit
Performance	Free Cash Flow	\$18.3B	Cash after capex
Performance	Operating Cash Flow	\$19.0B	Cash from operations
Profitability	Gross Margin	71.6%	Gross profit margin
Profitability	Operating Margin	34.1%	Operating efficiency
Profitability	Profit Margin	6.9%	Net margin
Profitability	ROE	6225.0%	Return on equity
Profitability	ROA	9.8%	Return on assets
Profitability	ROIC	N/A	Return on invested capital
Balance Sheet	Total Assets	\$0.0B	Total assets
Balance Sheet	Total Liabilities	\$0.0B	Total liabilities
Balance Sheet	Total Debt	\$68.4B	Total debt outstanding
Balance Sheet	Cash & Equivalents	\$5.3B	Liquid assets
Balance Sheet	Book Value/Share	\$-1.85	Net worth per share
Balance Sheet	Current Ratio	0.67	Current assets/liabilities
Balance Sheet	Quick Ratio	0.41	Liquid assets/liabilities
Balance Sheet	Debt/Equity	0.00	Leverage ratio
Market	Beta	0.33	Market correlation
Market	52-Week High	\$244.81	Annual high
Market	52-Week Low	\$164.39	Annual low

Market	Avg Volume	7.2M	Average daily volume
Market	Shares Outstanding	1.8B	Total shares
Market	Float	1.8B	Tradeable shares
Market	Short Interest	1.4%	Shares sold short
Market	Institutional Own.	76.4%	Institution held
Analysts	Coverage Count	29	Number of analysts
Analysts	Average Rating	1.8	1=Strong Buy, 5=Sell
Analysts	Buy/Hold/Sell	20/8/1	Rating distribution
Analysts	Target Price	\$249.14	Average price target
Analysts	Target High	\$299.00	Highest target
Analysts	Target Low	\$184.00	Lowest target
Other	Next Earnings	May 01, 2026	Earnings report date
Other	Dividend Yield	3.30%	Annual dividend rate
Other	Ex-Dividend Date	1776211200	Next ex-div date

REFERENCE: APPENDIX C - Complete Trade History

Detailed Backtesting Results and Trade Log

Entry	Exit	Type	Entry \$	Exit \$	Past P&L %	Past P&L \$
2019-08-07	2020-03-13	CONFLUENCE	\$49.14	\$66.93	+36.2%	+\$1440
2020-05-12	2021-09-08	CONFLUENCE	\$71.97	\$93.28	+29.6%	+\$895
2021-11-02	2022-05-23	CONFLUENCE	\$99.69	\$129.04	+29.4%	+\$2054
2022-07-07	2022-08-04	GOLDEN_CROSS	\$132.50	\$122.23	-7.8%	-\$462
2022-09-30	2023-01-24	CONFLUENCE	\$118.08	\$132.51	+12.2%	+\$635
2023-03-03	2023-03-09	GOLDEN_CROSS	\$140.02	\$132.21	-5.6%	-\$469
2023-06-01	2024-04-16	CONFLUENCE	\$120.83	\$153.15	+26.8%	+\$1649
2024-04-26	2024-11-13	CONFLUENCE	\$150.40	\$163.28	+8.6%	+\$580
2025-01-22	2025-04-10	CONFLUENCE	\$163.71	\$168.55	+3.0%	+\$223
2025-09-11	2026-03-23	CONFLUENCE	\$216.90	\$204.93	-5.5%	-\$503

IMPORTANT DISCLAIMER

Disclaimer: This report is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Technical analysis based on historical data through 2026-03-27. Fundamental data auto-fetched from Yahoo Finance. Please conduct your own due diligence before making investment decisions.

Next Earnings: May 01, 2026

Report Generated: March 29, 2026 at 12:21 PM